
Roger Olsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5797237/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Seamless integration of bioelectronic interface in an animal model via in vivo polymerization of conjugated oligomers. Bioactive Materials, 2022, 10, 107-116.	15.6	10
2	High PGD2 receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model. British Journal of Cancer, 2022, 126, 586-597.	6.4	7
3	Organic electrochemical neurons and synapses with ion mediated spiking. Nature Communications, 2022, 13, 901.	12.8	110
4	Method Matters: Exploring Alkoxysulfonate-Functionalized Poly(3,4-ethylenedioxythiophene) and Its Unintentional Self-Aggregating Copolymer toward Injectable Bioelectronics. Chemistry of Materials, 2022, 34, 2752-2763.	6.7	5
5	Rational Materials Design for In Operando Electropolymerization of Evolvable Organic Electrochemical Transistors. Advanced Functional Materials, 2022, 32, .	14.9	6
6	A Biomimetic Evolvable Organic Electrochemical Transistor. Advanced Electronic Materials, 2021, 7, 2001126.	5.1	26
7	Identification of potential chemical compounds enhancing generation of enucleated cells from immortalized human erythroid cell lines. Communications Biology, 2021, 4, 677.	4.4	7
8	FRET-Based Screening Identifies p38 MAPK and PKC Inhibition as Targets for Prevention of Seeded α-Synuclein Aggregation. Neurotherapeutics, 2021, 18, 1692-1709.	4.4	6
9	Discovery of Procognitive Antipsychotics by Combining Muscarinic M1 Receptor Structure–Activity Relationship with Systems Response Profiles in Zebrafish Larvae. ACS Chemical Neuroscience, 2020, 11, 173-183.	3.5	3
10	Enantiomeric N-substituted phthalimides with excitatory amino acids protect zebrafish larvae against PTZ-induced seizures. European Journal of Pharmacology, 2020, 888, 173489.	3.5	5
11	Diamond Blackfan anemia is mediated by hyperactive Nemo-like kinase. Nature Communications, 2020, 11, 3344.	12.8	10
12	Tumour suppressor 15-hydroxyprostaglandin dehydrogenase induces differentiation in colon cancer via GLI1 inhibition. Oncogenesis, 2020, 9, 74.	4.9	9
13	Tumourâ€suppressive effect of oestrogen receptor β in colorectal cancer patients, colon cancer cells, and a zebrafish model. Journal of Pathology, 2020, 251, 297-309.	4.5	19
14	A Phenotypic Screening Assay Identifies Modulators of Diamond Blackfan Anemia. SLAS Discovery, 2019, 24, 304-313.	2.7	9
15	Identification of Potential Chemical Compounds Able to Trigger Enucleation of Immortalized Human Erythroid Cell Lines. Blood, 2019, 134, 951-951.	1.4	1
16	Abstract 2997: 15-hydroxyprostaglandin dehydrogenase induced differentiation in colon cancer cells is regulated via Gli1. , 2019, , .		0
17	Evaluation of Drug Exposure and Metabolism in Locust and Zebrafish Brains Using Mass Spectrometry Imaging. ACS Chemical Neuroscience, 2018, 9, 1994-2000.	3.5	18
18	Osmotic Concentration of Zebrafish (Danio rerio) Body Fluids Is Lower in Larvae than in Adults. Zebrafish, 2018, 15, 9-14.	1.1	3

#	Article	IF	CITATIONS
19	Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity. BMC Cancer, 2018, 18, 466.	2.6	4
20	Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs. Blood, 2018, 132, 753-753.	1.4	1
21	Ligand Dependent Switch from RXR Homo- to RXR-NURR1 Heterodimerization. ACS Chemical Neuroscience, 2017, 8, 2065-2077.	3.5	19
22	Action sequencing in the spontaneous swimming behavior of zebrafish larvae - implications for drug development. Scientific Reports, 2017, 7, 3191.	3.3	17
23	BORTEZOMIB PREVENTS DEVELOPMENT OF CYTARABINE RESISTANCE IN A MANTLE CELL LYMPHOMA <i>IN VITRO</i> MODEL. Hematological Oncology, 2017, 35, 400-401.	1.7	0
24	Small molecules increase direct neural conversion of human fibroblasts. Scientific Reports, 2016, 6, 38290.	3.3	48
25	Estrogen Receptor Beta Selective Agonists as Agents to Treat Chemotherapeutic-Induced Neuropathic Pain. ACS Chemical Neuroscience, 2016, 7, 1180-1187.	3.5	29
26	Regio- and Stereoselective Alkylation of Pyridine- <i>N</i> -oxides: Synthesis of Substituted Piperidines and Pyridines. Organic Letters, 2016, 18, 6228-6231.	4.6	9
27	Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma. BMC Cancer, 2016, 16, 493.	2.6	4
28	Small molecule screen identifies differentiationâ€promoting compounds targeting genetically diverse acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 342-346.	2.5	5
29	Chiral Dihydrobenzofuran Acids Show Potent Retinoid X Receptor–Nuclear Receptor Related 1 Protein Dimer Activation. Journal of Medicinal Chemistry, 2016, 59, 1232-1238.	6.4	14
30	An ex Vivo Model for Evaluating Blood–Brain Barrier Permeability, Efflux, and Drug Metabolism. ACS Chemical Neuroscience, 2016, 7, 668-680.	3.5	19
31	Behavioral Analysis of Dopaminergic Activation in Zebrafish and Rats Reveals Similar Phenotypes. ACS Chemical Neuroscience, 2016, 7, 633-646.	3.5	46
32	Resistance to Cytarabine in Mantle Cell Lymphoma Is Mediated By Down-Regulation of Deoxycytidine Kinase at the Protein Level. Blood, 2016, 128, 1769-1769.	1.4	1
33	Differentiation targeted compound screen of acute myeloid leukemia. Experimental Hematology, 2015, 43, S52.	0.4	Ο
34	Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators. Journal of Medicinal Chemistry, 2015, 58, 1569-1574.	6.4	18
35	Using visual lateralization to model learning and memory in zebrafish larvae. Scientific Reports, 2015, 5, 8667.	3.3	31
36	Therapeutic Targeting of Nuclear Î ³ -Tubulin in RB1-Negative Tumors. Molecular Cancer Research, 2015, 13, 1073-1082.	3.4	13

#	Article	IF	CITATIONS
37	Therapeutic Targeting of Nuclear γâ€ŧubulin in RB1â€negative Tumors. FASEB Journal, 2015, 29, 897.14.	0.5	0
38	Ciclopirox Ethanolamine Is a Novel Modifier of Human Hematopoietic Stem Cell Ex Vivo Expansion. Blood, 2015, 126, 36-36.	1.4	3
39	Impact of estrogen receptor beta activation on functional recovery after experimental stroke. Behavioural Brain Research, 2014, 261, 282-288.	2.2	14
40	Bexarotene prodrugs: Targeting through cleavage by NQO1 (DT-diaphorase). Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1944-1947.	2.2	13
41	Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression. Anticancer Research, 2014, 34, 5269-76.	1.1	10
42	The A-CD analogue of 16β,17α-estriol is a potent and highly selective estrogen receptor β agonist. MedChemComm, 2013, 4, 1439.	3.4	4
43	Low Dose Bexarotene Treatment Rescues Dopamine Neurons and Restores Behavioral Function in Models of Parkinson's Disease. ACS Chemical Neuroscience, 2013, 4, 1430-1438.	3.5	104
44	Nonsteroidal Selective Androgen Receptor Modulators and Selective Estrogen Receptor β Agonists Moderate Cognitive Deficits and Amyloid-β Levels in a Mouse Model of Alzheimer's Disease. ACS Chemical Neuroscience, 2013, 4, 1537-1548.	3.5	50
45	Enantioselective Synthesis of Substituted Piperidines by Addition of Aryl Grignard Reagents to Pyridine <i>N</i> -Oxides. Organic Letters, 2013, 15, 54-57.	4.6	28
46	Design of a Highly Selective and Potent Class of Nonâ€planar Estrogen Receptor β Agonists. ChemMedChem, 2013, 8, 1283-1294.	3.2	9
47	AC-186, a Selective Nonsteroidal Estrogen Receptor β Agonist, Shows Gender Specific Neuroprotection in a Parkinson's Disease Rat Model. ACS Chemical Neuroscience, 2013, 4, 1249-1255.	3.5	26
48	A Robust Screening Assay For Diamond Blackfan Anemia Candidate Drugs. Blood, 2013, 122, 2472-2472.	1.4	0
49	Selective Mode of Action of Guanidine-Containing Non-Peptides at Human NPFF Receptors. Journal of Medicinal Chemistry, 2012, 55, 6124-6136.	6.4	18
50	Discovery of potential antipsychotic agents possessing pro-cognitive properties. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 313-323.	3.0	7
51	Can α-synuclein be targeted in novel therapies for Parkinson's disease?. Expert Review of Neurotherapeutics, 2011, 11, 917-919.	2.8	11
52	Reactions between Grignard reagents and heterocyclic N-oxides: Stereoselective synthesis of substituted pyridines, piperidines, and piperazines. Organic and Biomolecular Chemistry, 2011, 9, 337-346.	2.8	59
53	Characterization of Highly Efficacious Allosteric Agonists of the Human Calcium-Sensing Receptor. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 275-284.	2.5	47
54	Complete Regioselective Addition of Grignard Reagents to Pyrazine <i>N</i> -Oxides, Toward an Efficient Enantioselective Synthesis of Substituted Piperazines. Organic Letters, 2010, 12, 284-286.	4.6	40

#	Article	IF	CITATIONS
55	Efficient, mild and completely regioselective synthesis of substituted pyridines. Chemical Communications, 2010, 46, 3384.	4.1	56
56	Asymmetric synthesis of a tricyclic benzofuran motif: a privileged core structure in biologically active molecules. Organic and Biomolecular Chemistry, 2010, 8, 4831.	2.8	17
57	Synthesis of substituted 4-pyridones and 4-aminopyridinium salts via a one-pot pyridine synthesis. Tetrahedron Letters, 2010, 51, 4218-4220.	1.4	7
58	Optimization of isochromanone based urotensin II receptor agonists. Bioorganic and Medicinal Chemistry, 2010, 18, 4844-4854.	3.0	11
59	Discovery of a class of calcium sensing receptor positive allosteric modulators; 1-(benzothiazol-2-yl)-1-phenylethanols. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5918-5921.	2.2	8
60	Neuropeptide FF Receptors Have Opposing Modulatory Effects on Nociception. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 244-254.	2.5	47
61	THE DIAGNOSTIC SIGNIFICANCE OF A HIGH ASAT/ALAT (GOT/GPT) RATIO IN PATIENTS WITH VERY HIGH SERUM AMINOTRANSFERASE LEVELS. Acta Medica Scandinavica, 2009, 195, 227-229.	0.0	23
62	The Regio―and Stereoselective Synthesis of <i>trans</i> â€2,3â€Dihydropyridine <i>N</i> â€oxides and Piperidines. Angewandte Chemie - International Edition, 2009, 48, 3288-3291.	13.8	43
63	Novel and potent small-molecule urotensin II receptor agonists. Bioorganic and Medicinal Chemistry, 2009, 17, 4657-4665.	3.0	7
64	Discovery of non-peptidergic MrgX1 and MrgX2 receptor agonists and exploration of an initial SAR using solid-phase synthesis. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1729-1732.	2.2	23
65	Synthesis, Structureâ^'Activity Relationships, and Characterization of Novel Nonsteroidal and Selective Androgen Receptor Modulators. Journal of Medicinal Chemistry, 2009, 52, 7186-7191.	6.4	36
66	Synthesis and Evaluation of Dibenzothiazepines: A Novel Class of Selective Cannabinoid-1 Receptor Inverse Agonists. Journal of Medicinal Chemistry, 2009, 52, 1975-1982.	6.4	33
67	Design, Synthesis, and Structureâ^'Activity Analysis of Isoform-Selective Retinoic Acid Receptor β Ligands. Journal of Medicinal Chemistry, 2009, 52, 1540-1545.	6.4	29
68	Discovery of Selective Nonpeptidergic Neuropeptide FF2 Receptor Agonists. Journal of Medicinal Chemistry, 2009, 52, 6511-6514.	6.4	27
69	Selective synthesis of 2-substituted pyridine N-oxides via directed ortho-metallation using Grignard reagents. Tetrahedron Letters, 2008, 49, 6901-6903.	1.4	32
70	Identification of novel selective V2 receptor non-peptide agonists. Biochemical Pharmacology, 2008, 76, 1134-1141.	4.4	6
71	Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist. European Journal of Pharmacology, 2008, 590, 423-429.	3.5	35
72	Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist. European Journal of Pharmacology, 2008, 592, 158-159.	3.5	23

#	Article	IF	CITATIONS
73	Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. Journal of Steroid Biochemistry and Molecular Biology, 2008, 109, 129-137.	2.5	23
74	Discovery of Potent and Selective Small-Molecule PAR-2 Agonists. Journal of Medicinal Chemistry, 2008, 51, 5490-5493.	6.4	36
75	Identification and Characterization of Novel Small-Molecule Protease-Activated Receptor 2 Agonists. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 799-808.	2.5	43
76	Identification of the First Synthetic Steroidogenic Factor 1 Inverse Agonists: Pharmacological Modulation of Steroidogenic Enzymes. Molecular Pharmacology, 2008, 73, 900-908.	2.3	43
77	Pharmacology and Signaling Properties of Epidermal Growth Factor Receptor Isoforms Studied by Bioluminescence Resonance Energy Transfer. Molecular Pharmacology, 2007, 71, 508-518.	2.3	24
78	Identification of the Atypical L-Type Ca2+ Channel Blocker Diltiazem and Its Metabolites As Ghrelin Receptor Agonists. Molecular Pharmacology, 2007, 72, 380-386.	2.3	11
79	Synthesis of 2-Substituted Pyridines via a Regiospecific Alkylation, Alkynylation, and Arylation of PyridineN-Oxides. Organic Letters, 2007, 9, 1335-1337.	4.6	114
80	Reaction of pyridine N-oxides with Grignard reagents: a stereodefined synthesis of substituted dienal oximes. Tetrahedron Letters, 2007, 48, 6941-6944.	1.4	33
81	Design, parallel synthesis and SAR of novel urotensin II receptor agonists. European Journal of Medicinal Chemistry, 2007, 42, 276-285.	5.5	46
82	Novel Potent and Efficacious Nonpeptidic Urotensin II Receptor Agonists. Journal of Medicinal Chemistry, 2006, 49, 2232-2240.	6.4	38
83	Iron-Catalyzed Cross-Coupling of Imidoyl Chlorides with Grignard Reagents. Organic Letters, 2006, 8, 1771-1773.	4.6	95
84	lsochromanone-based urotensin-II receptor agonists. Bioorganic and Medicinal Chemistry, 2005, 13, 3057-3068.	3.0	41
85	Identification of novel subtype selective RAR agonists. Biochemical Pharmacology, 2005, 71, 156-162.	4.4	29
86	Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist. Journal of Medicinal Chemistry, 2005, 48, 7517-7519.	6.4	68
87	Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 1278-1287.	2.5	163
88	Funcational assay platform to identify novel inhibitors of receptor tyrosine kinases. Journal of Clinical Oncology, 2005, 23, 3144-3144.	1.6	0
89	The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology, 2004, 177, 207-216.	3.1	217
90	Solution-Phase Parallel Wittig Olefination: Synthesis of Substituted 1,2-Diarylethanes ChemInform, 2004, 35, no.	0.0	0

#	Article	IF	CITATIONS
91	Efficient Solution-Phase Parallel Synthesis of 4-Substituted N-Protected Piperidines ChemInform, 2004, 35, no.	0.0	0
92	A Combinatorial Scaffold Approach Based upon a Multicomponent Reaction. Organic Letters, 2003, 5, 1551-1554.	4.6	27
93	Efficient Solution-Phase Parallel Synthesis of 4-SubstitutedN-Protected Piperidines. European Journal of Organic Chemistry, 2003, 2003, 4586-4592.	2.4	29
94	A Novel Metal Iodide Promoted Three-Component Synthesis of Substituted Pyrrolidines ChemInform, 2003, 34, no.	0.0	0
95	One-Pot Three-Component Reaction for the Synthesis of α-(Aminoethyl)-α,β-enones ChemInform, 2003, 34, no.	0.0	Ο
96	Solution-Phase Parallel Wittig Olefination:  Synthesis of Substituted 1,2-Diarylethanes. ACS Combinatorial Science, 2003, 5, 606-609.	3.3	16
97	One-Pot Three-Component Reaction for the Synthesis of α-(Aminoethyl)-α,β-enones. Organic Letters, 2002, 4, 4333-4336.	4.6	31
98	Discovery of the First Nonpeptide Agonist of the GPR14/Urotensin-II Receptor:Â 3-(4-Chlorophenyl)-3-(2-) Tj ETQ	q0 0 0 rgB	T /Qyerlock 1
99	A Novel Metal Iodide Promoted Three-Component Synthesis of Substituted Pyrrolidines. Organic Letters, 2002, 4, 3147-3150.	4.6	127
100	General combinatorial synthesis of tertiary amines on solid support. A novel conditional release strategy based on traceless linking at nitrogen. Tetrahedron Letters, 2001, 42, 133-136.	1.4	34
101	Microwave-assisted solvent-free parallel synthesis of thioamides. Tetrahedron Letters, 2000, 41, 7947-7950.	1.4	46
102	Multistep solution-Phase parallel synthesis of spiperone analogues. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2435-2439.	2.2	10
103	Temporary in Situ Aluminum and Zinc Tethering in Dielsâ ^{~,} Alder Reactions. Organic Letters, 2000, 2, 1283-1286.	4.6	29
104	Organotitanium-induced stereoselective alkylative endo-cleavage of benzyl pentopyranosides. Carbohydrate Research, 1998, 307, 13-18.	2.3	10
105	Endocyclic cleavage of glycosides. VI. Substituent effects of the alkylative endocyclic cleavage of glycosides. Tetrahedron, 1998, 54, 3935-3954.	1.9	18
106	Chelation-controlled regioselective endo cleavage and stereoselective C-1 alkylation of pentofuranosides. Journal of the Chemical Society Perkin Transactions 1, 1998, , 785-790.	0.9	10
107	Alkylative Cleavage of the Endo-Cyclic CO Bond in Lactol Ethers Employing Organometallic Reagents Acta Chemica Scandinavica, 1998, 52, 172-174.	0.7	3
108	Combined videomanometric identification of abnormalities related to pharyngeal retention. Academic Radiology, 1997, 4, 349-354.	2.5	30

#	Article	IF	CITATIONS
109	Videophlebography with Foot Venous Pressure Measurements: Description of a Technique for Diagnosing Venous Dysfunction. Phlebology, 1997, 12, 100-106.	1.2	5
110	Surgical removal of a skin cancer involving the superior sagittal sinus: gradual obstruction of the sinus using miniature tissue expanders. European Journal of Plastic Surgery, 1997, 20, 89-91.	0.6	1
111	Is a hydrogen-bonded carbene an intermediate in the organoaluminum-induced ring opening of pyranosides? ring opening of pyranosides?. Tetrahedron Letters, 1997, 38, 5701-5704.	1.4	9
112	Videomanometric aspects of pharyngeal constrictor activity. Dysphagia, 1996, 11, 83-86.	1.8	27
113	Hepatitis and Cancer: Genetic Aspects. Scandinavian Journal of Gastroenterology, 1996, 31, 115-120.	1.5	3
114	Solid-state computerized manometry improves diagnostic yield in pharyngeal dysphagia: simultaneous videoradiography and manometry in dysphagia patients with normal barium swallows. Abdominal Imaging, 1995, 20, 230-235.	2.0	42
115	Simultaneous videoradiography and pharyngeal solid state manometry (videomanometry) in 25 nondysphagic volunteers. Dysphagia, 1995, 10, 36-41.	1.8	45
116	Videomanometry of the pharynx in dysphagic patients with a posterior cricopharyngeal indentation. Academic Radiology, 1995, 2, 597-601.	2.5	28
117	Pharyngeal Solid-State Manometry Catheter Movement During Swallowing in Dysphagic and Nondysphagic Participants. Academic Radiology, 1994, 1, 339-344.	2.5	10
118	Simultaneous videoradiography and computerized pharyngeal manometryvideomanometry. Acta Radiologica, 1994, 35, 30-4.	1.1	8
119	An enantiospecific synthesis of D-erythro-sphingosine from D-tartaric acid. Tetrahedron, 1993, 49, 6645-6650.	1.9	42
120	Liver damage from flucloxacillin, cloxacillin and dicloxacillin. Journal of Hepatology, 1992, 15, 154-161.	3.7	133
121	Release of immunoreactive canine leukocyte elastase normally and in endotoxin and pancreatitic shock. Scandinavian Journal of Clinical and Laboratory Investigation, 1990, 50, 35-42.	1.2	7
122	Clinical Experience with Isolated Hyperbilirubinemia. Scandinavian Journal of Gastroenterology, 1989, 24, 617-622.	1.5	7
123	Gilbert's syndromedoes it exist? A study of the prevalence of symptoms in Gilbert's syndrome. Acta Medica Scandinavica, 1988, 224, 485-90.	0.0	2
124	Anticonvulsant-induced liver damage. American Journal of Gastroenterology, 1988, 83, 576-7.	0.4	9
125	Prevalence of Markers of Hepatotrophic Viruses in Alcoholics with Symptomatic Liver Cirrhosis or Pancreatitis. Scandinavian Journal of Gastroenterology, 1984, 19, 588-590.	1.5	11
126	Alcohol Consumption Pattern and Serum Lipids in Alcoholic Cirrhosis and Pancreatitis. Scandinavian Journal of Gastroenterology, 1984, 19, 582-587.	1.5	28

#	Article	IF	CITATIONS
127	Observations of Increased Levels of Blood Coagulation Factors and Other Plasma Proteins in Cholestatic Liver Disease. Scandinavian Journal of Gastroenterology, 1976, 11, 391-396.	1.5	18